ArticleBiochemistry2006
Secretin receptor oligomers form intracellularly during maturation through receptor core domains.
Article in Biochemistry, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 30 citations in OpenAlex.
- Structure and Function of Cross-class Complexes of G Protein-coupled Secretin and Angiotensin 1a Receptors.The Journal of biological chemistry · 2016Article
- Oligomerization of Family B GPCRs: Exploration in Inter-Family Oligomer Formation.Frontiers in endocrinology · 2015Review
- Transmembrane peptides as unique tools to demonstrate the in vivo action of a cross-class GPCR heterocomplex.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2014Article
- BRET Biosensor Analysis of Receptor Tyrosine Kinase Functionality.Frontiers in endocrinology · 2013Article
- Ligand binding and activation of the secretin receptor, a prototypic family B G protein-coupled receptor.British journal of pharmacology · 2012Review
- SUMO downregulates GLP-1-stimulated cAMP generation and insulin secretion.American journal of physiology. Endocrinology and metabolism · 2012Article
- Receptor oligomerization: from early evidence to current understanding in class B GPCRs.Frontiers in endocrinology · 2012Article
- Receptor oligomerization in family B1 of G-protein-coupled receptors: focus on BRET investigations and the link between GPCR oligomerization and binding cooperativity.Frontiers in endocrinology · 2012Article
- Importance of lipid-exposed residues in transmembrane segment four for family B calcitonin receptor homo-dimerization.Regulatory peptides · 2010Article
- Dimeric arrangement of the parathyroid hormone receptor and a structural mechanism for ligand-induced dissociation.The Journal of biological chemistry · 2010Article
- Increasingly accurate dynamic molecular models of G-protein coupled receptor oligomers: Panacea or Pandora's box for novel drug discovery?Life sciences · 2010Review
- Molecular basis of association of receptor activity-modifying protein 3 with the family B G protein-coupled secretin receptor.Biochemistry · 2009Article
- Functional importance of a structurally distinct homodimeric complex of the family B G protein-coupled secretin receptor.Molecular pharmacology · 2009Article
- Dimerization in the absence of higher-order oligomerization of the G protein-coupled secretin receptor.Biochimica et biophysica acta · 2008Article
- Pattern of intra-family hetero-oligomerization involving the G-protein-coupled secretin receptor.Journal of molecular neuroscience : MN · 2008Article
- A day in the life of a G protein-coupled receptor: the contribution to function of G protein-coupled receptor dimerization.British journal of pharmacology · 2008Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Oligomerization of numerous G protein-coupled receptors has been documented, including the prototypic family B secretin receptor. The clinical significance of oligomerization of this receptor became clear with the recent observation that a misspliced form present in pancreatic cancer could associate with the wild-type receptor and act as a dominant negative inhibitor of its normal growth inhibitory function. Our goal was to explore the molecular mechanism of this interaction using bioluminescence (BRET) and fluorescence (FRET) resonance energy transfer and fluorescence microscopy with a variety of receptor constructs tagged with luciferase or cyan or yellow fluorescent proteins. BRET signals comparable to those obtained from cells coexpressing differentially tagged wild-type receptors were observed for similarly tagged secretin receptors in which all or part of the amino-terminal domain was deleted. As expected, neither of these constructs bound secretin, and only the partially truncated construct sorted to the plasma membrane. Receptors lacking the majority of the carboxyl-terminal domain, including that important for phosphorylation-mediated desensitization, also produced BRET signals above background. These findings suggested that the receptor's membrane-spanning core is responsible for secretin receptor oligomerization. Interestingly, alanine substitutions for a -GxxxG- helix interaction motif in transmembrane segment 7 created nonfunctional receptors that were capable of forming oligomers. Furthermore, treatment of receptor-expressing cells with brefeldin A did not eliminate the BRET signals, and morphologic FRET experiments confirmed the expected subcellular localizations of receptor oligomers. We conclude that secretin receptor oligomerization occurs through -GxxxG- motif-independent interactions of transmembrane segments during the maturation of nascent molecules.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.